AFT to launch Maxigesic® Rapid in the United States

AFT Pharmaceuticals Limited,
Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com








3 June 2024
AFT to launch Maxigesic
®
Rapid in the United States.
AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today announces an agreement
with Alexso to distribute Combogesic® (Maxigesic Rapid Tablets) in the United
States, the largest pharma market in the world
1
.
AFT Pharmaceuticals Managing Director Dr Hartley Atkinson said: “We are
delighted to announce our partnership with Alexso, an established
pharmaceutical distribution company which prioritizes non-opioid pain
management solutions.
We are pleased to be launching our second patented pharmaceutical into
the United States market, which we anticipate will occur during this financial
year.”
"Troy Farahmand, President of Alexso, stated: 'We are thrilled to introduce
Combogesic to our portfolio of non-opioid pain management solutions. This
partnership with AFT Pharmaceuticals aligns perfectly with our commitment to
offering physicians effective alternatives to opioids. Combogesic will play a
crucial role in our mission to combat pain while reducing the reliance on
addictive opioid medications.”.
AFT’s negotiations continue to progress with other distributors for additional
specific market channels in the United States.



For and on behalf of AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial
Officer.

For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232

Footnote
1.https://www.statista.com/statistics/245473/market-share-of-the-leading-10-global-
pharmaceutical-markets/

AFT Pharmaceuticals Limited,
Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com



About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets, and
distributes a broad portfolio of pharmaceutical products across a wide range of
therapeutic categories which are distributed across all major pharmaceutical
distribution channels: over the counter (OTC), prescription and hospital. Our product
portfolio comprises both proprietary and in-licensed products, and includes patented,
branded, and generic drugs
1
. Our business model is to develop and in-license
products for sale by our own dedicated sales teams in our home markets of Australia
and New Zealand and in certain Southeast Asian markets, and to out-license our
products to local licensees and distributors to over 125 countries around the world. For
more information about the company, visit our website www.aftpharm.com.

About Alexso
At Alexso, Inc., our mission is to be a leading pharmaceutical wholesale distribution
company that prioritizes non-opioid pain management solutions. Through our
unwavering commitment to excellence, we aim to provide healthcare professionals
with a diverse range of specialized products and services, catering to unique
marketing niches. By fostering innovation, promoting patient well-being, and building
strong partnerships, we strive to positively impact communities and advance the field
of pain management, ultimately improving lives and ensuring a healthier tomorrow.